These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 15009802)

  • 1. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
    Davis JE; Moss DJ
    Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Epstein-Barr virus-associated cancers in children.
    Straathof KC; Bollard CM; Rooney CM; Heslop HE
    Oncologist; 2003; 8(1):83-98. PubMed ID: 12604735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
    Burns DM; Crawford DH
    Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.
    Vickers MA; Wilkie GM; Robinson N; Rivera N; Haque T; Crawford DH; Barry J; Fraser N; Turner DM; Robertson V; Dyer P; Flanagan P; Newlands HR; Campbell J; Turner ML
    Br J Haematol; 2014 Nov; 167(3):402-10. PubMed ID: 25066775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory T cells and EBV associated malignancies.
    Li J; Qian CN; Zeng YX
    Int Immunopharmacol; 2009 May; 9(5):590-2. PubMed ID: 19539572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
    Khanna R; Bell S; Sherritt M; Galbraith A; Burrows SR; Rafter L; Clarke B; Slaughter R; Falk MC; Douglass J; Williams T; Elliott SL; Moss DJ
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10391-6. PubMed ID: 10468618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
    Sun Q; Burton R; Reddy V; Lucas KG
    Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection.
    Mautner J; Bornkamm GW
    Eur J Cell Biol; 2012 Jan; 91(1):31-5. PubMed ID: 21458882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for Epstein-Barr virus-associated malignancies.
    Long HM; Parsonage G; Fox CP; Lee SP
    Drug News Perspect; 2010 May; 23(4):221-8. PubMed ID: 20520851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for EBV-associated malignancies.
    Merlo A; Turrini R; Dolcetti R; Zanovello P; Rosato A
    Int J Hematol; 2011 Mar; 93(3):281-293. PubMed ID: 21336546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus, B cell lymphoproliferative disease, and SCID mice: modeling T cell immunotherapy in vivo.
    Johannessen I; Bieleski L; Urquhart G; Watson SL; Wingate P; Haque T; Crawford DH
    J Med Virol; 2011 Sep; 83(9):1585-96. PubMed ID: 21739450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
    Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
    Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children.
    Chiou FK; Beath SV; Wilkie GM; Vickers MA; Morland B; Gupte GL
    Pediatr Transplant; 2018 Mar; 22(2):. PubMed ID: 29388302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of EBV-specific CTLs suitable for adoptive immunotherapy of EBV-associated lymphoproliferative disease following allogeneic transplantation.
    Hoffmann T; Russell C; Vindelov L
    APMIS; 2002 Feb; 110(2):148-57. PubMed ID: 12064870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infusions of Epstein-Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases.
    Kim N; Sohn HJ; Oh JH; Jeon YW; Lee HJ; Cho HI; Chung BH; Yang CW; Kim TG; Cho SG
    Int J Hematol; 2018 May; 107(5):596-603. PubMed ID: 29188583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
    Gustafsson A; Levitsky V; Zou JZ; Frisan T; Dalianis T; Ljungman P; Ringden O; Winiarski J; Ernberg I; Masucci MG
    Blood; 2000 Feb; 95(3):807-14. PubMed ID: 10648390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy.
    Sherritt MA; Bharadwaj M; Burrows JM; Morrison LE; Elliott SL; Davis JE; Kear LM; Slaughter RE; Bell SC; Galbraith AJ; Khanna R; Moss DJ
    Transplantation; 2003 May; 75(9):1556-60. PubMed ID: 12792514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EBV specific CTL: a model for immune therapy.
    Rooney CM; Heslop HE; Brenner MK
    Vox Sang; 1998; 74 Suppl 2():497-8. PubMed ID: 9704488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication.
    Comoli P; Labirio M; Basso S; Baldanti F; Grossi P; Furione M; Viganò M; Fiocchi R; Rossi G; Ginevri F; Gridelli B; Moretta A; Montagna D; Locatelli F; Gerna G; Maccario R
    Blood; 2002 Apr; 99(7):2592-8. PubMed ID: 11895798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.